Literature DB >> 18816606

Preferential central nucleation of type 2 myofibers is an invariable feature of myotonic dystrophy type 2.

Valerio Pisani1, Maria Beatrice Panico1, Chiara Terracciano1, Emanuela Bonifazi2, Giovanni Meola3, Giuseppe Novelli2, Giorgio Bernardi1, Corrado Angelini4, Roberto Massa1.   

Abstract

The clinical features of myotonic dystrophy type 1 (DM1) and type 2 (DM2) may present striking similarity, whereas, in some cases, the DM2 phenotype may be so mild that the diagnosis may be missed. Therefore, the identification of disease-specific histopathological patterns for DM1 and DM2 may help clinicians to correctly address genetic studies. We performed a comparative morphological and morphometric analysis on muscle biopsies from 10 DM1 and 11 DM2 patients, comparing type 1 and type 2 fibers as to: fiber type predominance, transverse diameter, atrophy and hypertrophy factors, and prevalence of central nuclei. In DM1 cases we observed preferential type 1 fiber atrophy and a higher prevalence of central nucleation among type 1 fibers in all cases. In DM2 muscle biopsies, high rates of atrophic and hypertrophic type 2 fibers were observed in most cases, and preferential central nucleation in type 2 fibers was present in all cases. As opposed to DM1, in which type 1 fibers display most of the histological changes, preferential atrophy and hypertrophy of type 2 fibers may be considered as markers of DM2. A higher prevalence of central nuclei among hypertrophic type 2 fibers has a predictive value for the diagnosis of DM2. Thus, morphometric and fiber type-based histological analysis of muscle biopsies may help differentiate between DM1 and DM2 and guide molecular analysis.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18816606     DOI: 10.1002/mus.21122

Source DB:  PubMed          Journal:  Muscle Nerve        ISSN: 0148-639X            Impact factor:   3.217


  21 in total

1.  Co-segregation of DM2 with a recessive CLCN1 mutation in juvenile onset of myotonic dystrophy type 2.

Authors:  Rosanna Cardani; Marzia Giagnacovo; Annalisa Botta; Fabrizio Rinaldi; Alessandra Morgante; Bjarne Udd; Olayinka Raheem; Sini Penttilä; Tiina Suominen; Laura V Renna; Valeria Sansone; Enrico Bugiardini; Giuseppe Novelli; Giovanni Meola
Journal:  J Neurol       Date:  2012-03-10       Impact factor: 4.849

Review 2.  Myotonic dystrophy type 2 and modifier genes: an update on clinical and pathomolecular aspects.

Authors:  Giovanni Meola; Rosanna Cardani
Journal:  Neurol Sci       Date:  2017-01-11       Impact factor: 3.307

3.  Validation of sensitivity and specificity of tetraplet-primed PCR (TP-PCR) in the molecular diagnosis of myotonic dystrophy type 2 (DM2).

Authors:  Claudio Catalli; Alessandra Morgante; Raniero Iraci; Fabrizio Rinaldi; Annalisa Botta; Giuseppe Novelli
Journal:  J Mol Diagn       Date:  2010-07-08       Impact factor: 5.568

Review 4.  Muscle biopsy evaluation in neuromuscular disorders.

Authors:  Nanette C Joyce; Björn Oskarsson; Lee-Way Jin
Journal:  Phys Med Rehabil Clin N Am       Date:  2012-08       Impact factor: 1.784

Review 5.  Biomolecular diagnosis of myotonic dystrophy type 2: a challenging approach.

Authors:  Giovanni Meola; Fiammetta Biasini; Rea Valaperta; Elena Costa; Rosanna Cardani
Journal:  J Neurol       Date:  2017-05-26       Impact factor: 4.849

6.  Extraocular muscles in patients with infantile nystagmus: adaptations at the effector level.

Authors:  Kathleen T Berg; David G Hunter; Erick D Bothun; Rosalia Antunes-Foschini; Linda K McLoon
Journal:  Arch Ophthalmol       Date:  2012-03

7.  Single-nucleus cross-tissue molecular reference maps toward understanding disease gene function.

Authors:  Gökcen Eraslan; Eugene Drokhlyansky; Shankara Anand; Evgenij Fiskin; Ayshwarya Subramanian; Michal Slyper; Jiali Wang; Ayellet V Segrè; François Aguet; Orit Rozenblatt-Rosen; Kristin G Ardlie; Aviv Regev; Nicholas Van Wittenberghe; John M Rouhana; Julia Waldman; Orr Ashenberg; Monkol Lek; Danielle Dionne; Thet Su Win; Michael S Cuoco; Olena Kuksenko; Alexander M Tsankov; Philip A Branton; Jamie L Marshall; Anna Greka; Gad Getz
Journal:  Science       Date:  2022-05-13       Impact factor: 63.714

Review 8.  Skeletal muscle fiber type: using insights from muscle developmental biology to dissect targets for susceptibility and resistance to muscle disease.

Authors:  Jared Talbot; Lisa Maves
Journal:  Wiley Interdiscip Rev Dev Biol       Date:  2016-05-19       Impact factor: 5.814

9.  Alternative splicing of human insulin receptor gene (INSR) in type I and type II skeletal muscle fibers of patients with myotonic dystrophy type 1 and type 2.

Authors:  Massimo Santoro; Marcella Masciullo; Davide Bonvissuto; Maria Laura Ester Bianchi; Fabrizio Michetti; Gabriella Silvestri
Journal:  Mol Cell Biochem       Date:  2013-05-11       Impact factor: 3.396

10.  Differential features of muscle fiber atrophy in osteoporosis and osteoarthritis.

Authors:  C Terracciano; M Celi; D Lecce; J Baldi; E Rastelli; E Lena; R Massa; U Tarantino
Journal:  Osteoporos Int       Date:  2012-04-26       Impact factor: 4.507

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.